Epigenetic age is a cell-intrinsic property in transplanted human hematopoietic cells.
Level 3 - non-randomized controlled study
Observational follow-up cohort study of donor-recipient pairs post-transplantation
PubMed 30712319 · doi:10.1111/acel.12897
What was done
Blood DNA methylation data using the Horvath 353-CpG multitissue age predictor was analyzed in human allogeneic hematopoietic stem cell transplantation (HSCT) donor and recipient pairs. Pairs were evaluated across chronological age discrepancies ranging from 1 to 49 years, with long-term follow-up extending up to 17 years after transplantation, including pediatric recipients.
What was found
The DNA methylation age of reconstituted blood was not influenced by the recipient's chronological age or host environment up to 17 years after transplantation in patients without hematologic relapse. In recipients with leukemia relapse, blood DNA methylation age became unstable. Specific sample sizes, correlation coefficients, and quantitative error margins were not reported in the abstract.
Why it matters
This confirms that epigenetic aging in hematopoietic stem cells is primarily a cell-intrinsic process rather than one dictated by systemic, extracellular aging cues from the host body. It also indicates that tracking DNAm age deviations could assist in monitoring disease recurrence after HSCT.
Limits
The abstract does not disclose the sample size (number of donor-recipient pairs) or quantitative statistical parameters. Findings in reconstituted hematopoietic cells following conditioning and transplantation may not generalize to other solid organs or physiological aging in unperturbed tissues.
Cited by
- supports Following hematopoietic stem cell transplantation, reconstituted blood retains the epigenetic age of the donor rather than the recipient for decades.